PT  - JOURNAL ARTICLE
AU  - Bulvas, Miroslav
AU  - Sommerová, Zuzana
TI  - Acute and Subacute Ischemia of Lower Limbs: Angiography and Peripheral Hemodynamics
AID  - 10.1101/2023.02.21.23285736
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.21.23285736
4099  - http://medrxiv.org/content/early/2023/02/22/2023.02.21.23285736.short
4100  - http://medrxiv.org/content/early/2023/02/22/2023.02.21.23285736.full
AB  - Objective To identify pretreatment characteristics related to ischemia severity and symptoms duration in patients with acute (ALI) and subacute lower limb ischemia (SLI).Methods Comparative study, a part of prospective, single-arm, single-center trial of 316 consecutive patients with threatened extremities (all-comers, mean age: 70.9±12.0 years, range: 23-96; 184 men) of whom 99. 4 % suffered from acute or subacute supratibial occlusions (target occlusions).Results Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The value of ABI related to the number of occluded tibial arteries. Occlusion locations associated with ALI (IIA+IIB) were the aortoiliac segment and/or profunda femoris. Furthermore, ALI subjects presented additional infrapopliteal occlusion (acute and/or subacute), smaller number of patent tibial arteries and lower ABI.Conclusion Anatomically, the most important factor related to the ischemia severity and symptoms duration was the status of infrapopliteal vascular bed. The number of acutely, subacutely or chronically occluded tibial vessels was related to clinical categories of ALI and SLI and to ABI. This suggests that tibial reperfusion can be essential for the salvage of threatened limb and should be always considered.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN154967770Funding StatementNo funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:3rd Medical Faculty, Charles University Centralized Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesavailable on request